Compare Biogen Inc (BIIB) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Victoria's Secret & Co — how do they compare? Biogen Inc trades at $208.79 (market cap $30.13B), while Victoria's Secret & Co trades at $93.28 (market cap $7.48B). The key difference: Biogen Inc is far larger — about 4× Victoria's Secret & Co's market cap. Which is the better fit depends on your goals.
| BIIB | VSXY | |
|---|---|---|
Market Cap | $30.13B | $7.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $99.97 |
52-Week Low | $128.93 | $21.34 |
Enterprise Value | $37.20B | $10.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
VSXY trades at $94.6, down 5.37% today but near its 52-week high, with a bullish technical signal and strong support at $93. The company reported Q1 2026 EPS of $0.60, beating expectations, and shows improving net income margins. Analyst consensus is a Buy with a $91 target, while recent news highlights growth through data-driven marketing and international expansion.
Outlook is positive with earnings momentum and international growth, but risks include high valuation (P/E 37.51) and competitive pressures. Investors may find opportunity in continued execution, though margin sustainability and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
